Expert guidance on the differential diagnosis of neuroleptic malignant syndrome

被引：0

作者：

Orsolini, Laura ^{[1
]}

Volpe, Umberto ^{[1
]}

机构：

[1] Polytech Univ Marche, Dept Clin Neurosci, Unit Clin Psychiat, DIMSC, I-60126 Ancona, Italy

来源：

EXPERT REVIEW OF NEUROTHERAPEUTICS | 2025年 / 25卷 / 02期

关键词：

Antipsychotics; differential diagnosis; neuroleptic drugs; neuroleptic malignant syndrome; serotonergic syndrome; ANTIPSYCHOTICS; PROGRESSION;

D O I：

10.1080/14737175.2024.2417414

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：125 / 132

页数：8

共 13 条

[1]

Association AP, 2013, DIAGNOSTIC STAT MANU

[2]

Ayd FJ., 2020, J CLIN EXP PSYCHOPAT, V17, P189

[3] Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology [J].

Barnes, Thomas R. E. ;

Drake, Richard ;

Paton, Carol ;

Cooper, Stephen J. ;

Deakin, Bill ;

Ferrier, I. Nicol ;

Gregory, Catherine J. ;

Haddad, Peter M. ;

Howes, Oliver D. ;

Jones, Ian ;

Joyce, Eileen M. ;

Lewis, Shon ;

Lingford-Hughes, Anne ;

MacCabe, James H. ;

Owensm, David Cunningham ;

Patel, Maxine X. ;

Sinclair, Julia M. A. ;

Stone, James M. ;

Talbot, Peter S. ;

Upthegrove, Rachel ;

Wieck, Angelika ;

Yung, Alison R. .

JOURNAL OF PSYCHOPHARMACOLOGY, 2020, 34 (01) :3-78

[4]

Carroll B T, 2000, CNS Spectr, V5, P26

[5] Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort [J].

Guinart, Daniel ;

Taipale, Heidi ;

Rubio, Jose M. ;

Tanskanen, Antti ;

Correll, Christoph U. ;

Tiihonen, Jari ;

Kane, John M. .

SCHIZOPHRENIA BULLETIN, 2021, 47 (06) :1621-1630

[6] The neuroleptic malignant syndrome-a systematic case series analysis focusing on therapy regimes and outcome [J].

Kuhlwilm, L. ;

Schoenfeldt-Lecuona, C. ;

Gahr, M. ;

Connemann, B. J. ;

Keller, F. ;

Sartorius, A. .

ACTA PSYCHIATRICA SCANDINAVICA, 2020, 142 (03) :233-241

[7] The role of antipsychotics and other drugs on the development and progression of neuroleptic malignant syndrome [J].

Kyotani, Yoji ;

Zhao, Jing ;

Nakahira, Kiichi ;

Yoshizumi, Masanori .

SCIENTIFIC REPORTS, 2023, 13 (01)

[8] An update of safety of clinically used atypical antipsychotics [J].

Orsolini, L. ;

Tomasetti, C. ;

Valchera, A. ;

Vecchiotti, R. ;

Matarazzo, I. ;

Vellante, F. ;

Iasevoli, F. ;

Buonaguro, E. F. ;

Fornaro, M. ;

Fiengo, A. L. C. ;

Martinotti, G. ;

Mazza, M. ;

Perna, G. ;

Carano, A. ;

De Bartolomeis, A. ;

Di Giannantonio, M. ;

De Berardis, D. .

EXPERT OPINION ON DRUG SAFETY, 2016, 15 (10) :1329-1347

[9] Up-to-date expert opinion on the safety of recently developed antipsychotics [J].

Orsolini, Laura ;

De Berardis, Domenico ;

Volpe, Umberto .

EXPERT OPINION ON DRUG SAFETY, 2020, 19 (08) :981-997

[10] Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: a Comparative Analysis [J].

Schoenfeldt-Lecuona, Carlos ;

Kuhlwilm, Lilli ;

Cronemeyer, Maximilian ;

Neu, Peter ;

Connemann, Bernhard J. ;

Gahr, Maximilian ;

Sartorius, Alexander ;

Muehlbauer, Viktoria .

PHARMACOPSYCHIATRY, 2020, 53 (02) :51-59

← 1 2 →